A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients

What's the purpose of this trial?

This is a single arm, open-label, multicenter phase I study to assess the safety, tolerability and preliminary efficacy of autologous T cells transduced with a specific γδTCR, i.e. TEG002, in a dose escalation and expansion study in relapsed/refractory Multiple Myeloma patients.

The study will comprise of a Dose Escalation Segment and an Expansion Segment. The study consists of a screening period, leukapheresis of mononuclear cells, and conditioning chemotherapy, followed by TEG002. All subjects continue to be followed regularly for safety and efficacy assessments until 1 year after TEG002 administration.

This trial is currently open and accepting patients.

What's being studied?

  • TEG002

Additional Trial Information

Phase 1

View More

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required. Create your account or call us today for help (888) 828-2206.

Inclusion Criteria:

  • Signed informed consent
  • Adult
  • Relapsed or refractory Multiple Myeloma as defined by the IMWG
  • Life expectancy ≥3 months
  • ECOG performance status 0 or 1
  • Adequate vital organ function
  • Adequate bone marrow function
  • Toxicities from prior/ongoing therapies recovered to ≤ Grade 2 or subject's baseline
  • WCBP and men who can father children must be willing and able to use adequate contraception

Exclusion Criteria:


  • Any uncontrolled medical or psychiatric disorder that would preclude participation as outlined
  • Pregnant or lactating women
  • Amyloidosis
  • Uncontrolled infection(s)
  • Active CNS disease
  • Previous allogeneic-HSCT
  • History of another primary malignancy that requires intervention beyond surveillance or that has not been in remission for at least 1 year.
  • Subjects that received experimental or systemic therapy < 14 days before TEG002 infusion
  • NYHA Class ≥ II
  • Patients depending on dialysis
  • Patients with a history of pulmonary embolism or deep vein thrombosis
  • T cell mediated active autoimmune disease OR any active autoimmune disease requiring immunosuppressive therapy

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.


Massachusetts General Hospital

Boston, MA

Open and Accepting

Beth Israel Deaconess Medical Center

Boston, MA

Open and Accepting

Dana-Farber Cancer Institute

Boston, MA

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message